Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Semaglutide Formulations (DV3396 vs PDS290)
NCT05232708Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the semaglutide concentration-time curve from time 0 until last quantifiable measurement and Maximum observed semaglutide concentration. Started Jan 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05232708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232708.